Induction 3D-chemoradiation (CRT) yields a high rate of pathologic complete response in stage IIB(Pancoast)/III NSCLC operable patients (pts) without increasing perioperative mortality after (bi-)lobectomy: A review of 107 cases treated in a community- based center

7704 Background: Optimal preoperative treatment for stage IIB/III NSCLC remains a subject of controversy. According to the results of INT0139 trial (Albain KS et al in Proc ASCO 2005, abstr #7014), induction CRT appears to be superior to chemotherapy alone (CT) in terms of pathologic complete response (or microscopic residual foci, pCR), but increases postoperative (postop) mortality after pneumonectomy. Methods: Pts were selected through a multidisciplinary committee according to functional and resecability criteria. Induction treatment comprised 45 Gy/25 fractions/5 weeks. RT delivered to the primary tumor and pathologic hilar and/or mediastinal nodes (CTV) with an extra-margin of 1 to 1.5 cm (PTV). A 3D 5-field technique was used for all patients with 8–25 MV photons. Concurrent CT regimen was Cisplatinum 20 mg/m2 and Etoposide 50 mg/m2 (PE), d1–5, d29–33. Surgery was performed 4 to 6 weeks after CRT completion in deemed resectable pts. Inoperable pts were referred for a 20 Gy boost ± 1 extra-cycle of ...